Strategies for Early Vaccination During Novel Influenza Outbreaks.
Identifieur interne : 000181 ( Main/Exploration ); précédent : 000180; suivant : 000182Strategies for Early Vaccination During Novel Influenza Outbreaks.
Auteurs : M. Laskowski [Canada] ; Y. Xiao [États-Unis] ; N. Charland [Canada] ; S M Moghadas [Canada]Source :
- Scientific reports [ 2045-2322 ] ; 2015.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Canada, Enfant, Enfant d'âge préscolaire, Femelle, Flambées de maladies (), Grippe humaine (), Grippe humaine (immunologie), Humains, Jeune adulte, Mâle, Nourrisson, Nouveau-né, Pandémies (), Vaccination (), Vaccins antigrippaux (immunologie), Virus de la grippe A (immunologie).
- MESH :
English descriptors
- KwdEn :
- Adolescent, Adult, Canada, Child, Child, Preschool, Disease Outbreaks (prevention & control), Female, Humans, Infant, Infant, Newborn, Influenza A virus (immunology), Influenza Vaccines (immunology), Influenza, Human (immunology), Influenza, Human (prevention & control), Male, Middle Aged, Pandemics (prevention & control), Vaccination (methods), Young Adult.
- MESH :
- chemical , immunology : Influenza Vaccines.
- immunology : Influenza A virus, Influenza, Human.
- methods : Vaccination.
- prevention & control : Disease Outbreaks, Influenza, Human, Pandemics.
- Adolescent, Adult, Canada, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Young Adult.
Abstract
Ongoing research and technology developments hold the promise of rapid production and large-scale deployment of strain-specific or cross-protective vaccines for novel influenza viruses. We sought to investigate the impact of early vaccination on age-specific attack rates and evaluate the outcomes of different vaccination strategies that are influenced by the level of single or two-dose vaccine-induced protections. We developed and parameterized an agent-based model for two population demographics of urban and remote areas in Canada. Our results demonstrate that there is a time period before and after the onset of epidemic, during which the outcomes of vaccination strategies may differ significantly and are highly influenced by demographic characteristics. For the urban population, attack rates were lowest for children younger than 5 years of age in all vaccination strategies. However, for the remote population, the lowest attack rates were obtained for adults older than 50 years of age in most strategies. We found that the reduction of attack rates following the start of vaccination campaigns during the epidemic depends critically on the disease transmissibility, suggesting that for a sufficiently high transmissibility, vaccine delivery after the onset of epidemic has little or no effect, regardless of the population demographics.
DOI: 10.1038/srep18062
PubMed: 26658016
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Strategies for Early Vaccination During Novel Influenza Outbreaks.</title><author><name sortKey="Laskowski, M" sort="Laskowski, M" uniqKey="Laskowski M" first="M" last="Laskowski">M. Laskowski</name><affiliation wicri:level="1"><nlm:affiliation>Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada M3J 1P3.</nlm:affiliation><country>Canada</country><wicri:regionArea>Agent-Based Modelling Laboratory, York University, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Xiao, Y" sort="Xiao, Y" uniqKey="Xiao Y" first="Y" last="Xiao">Y. Xiao</name><affiliation wicri:level="1"><nlm:affiliation>Department of Mathematical Sciences, University of Cincinnati, Cincinnati OH, 45221 USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Mathematical Sciences, University of Cincinnati, Cincinnati OH</wicri:regionArea><wicri:noRegion>Cincinnati OH</wicri:noRegion></affiliation></author><author><name sortKey="Charland, N" sort="Charland, N" uniqKey="Charland N" first="N" last="Charland">N. Charland</name><affiliation wicri:level="1"><nlm:affiliation>Medicago Inc., 1020 Route de l'Église, Bureau 600, Quebec, Quebec, Canada GIV 3V9.</nlm:affiliation><country>Canada</country><wicri:regionArea>Medicago Inc., 1020 Route de l'Église, Bureau 600, Quebec, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Moghadas, S M" sort="Moghadas, S M" uniqKey="Moghadas S" first="S M" last="Moghadas">S M Moghadas</name><affiliation wicri:level="1"><nlm:affiliation>Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada M3J 1P3.</nlm:affiliation><country>Canada</country><wicri:regionArea>Agent-Based Modelling Laboratory, York University, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26658016</idno><idno type="pmid">26658016</idno><idno type="doi">10.1038/srep18062</idno><idno type="wicri:Area/Main/Corpus">000164</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000164</idno><idno type="wicri:Area/Main/Curation">000164</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000164</idno><idno type="wicri:Area/Main/Exploration">000164</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Strategies for Early Vaccination During Novel Influenza Outbreaks.</title><author><name sortKey="Laskowski, M" sort="Laskowski, M" uniqKey="Laskowski M" first="M" last="Laskowski">M. Laskowski</name><affiliation wicri:level="1"><nlm:affiliation>Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada M3J 1P3.</nlm:affiliation><country>Canada</country><wicri:regionArea>Agent-Based Modelling Laboratory, York University, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Xiao, Y" sort="Xiao, Y" uniqKey="Xiao Y" first="Y" last="Xiao">Y. Xiao</name><affiliation wicri:level="1"><nlm:affiliation>Department of Mathematical Sciences, University of Cincinnati, Cincinnati OH, 45221 USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Mathematical Sciences, University of Cincinnati, Cincinnati OH</wicri:regionArea><wicri:noRegion>Cincinnati OH</wicri:noRegion></affiliation></author><author><name sortKey="Charland, N" sort="Charland, N" uniqKey="Charland N" first="N" last="Charland">N. Charland</name><affiliation wicri:level="1"><nlm:affiliation>Medicago Inc., 1020 Route de l'Église, Bureau 600, Quebec, Quebec, Canada GIV 3V9.</nlm:affiliation><country>Canada</country><wicri:regionArea>Medicago Inc., 1020 Route de l'Église, Bureau 600, Quebec, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Moghadas, S M" sort="Moghadas, S M" uniqKey="Moghadas S" first="S M" last="Moghadas">S M Moghadas</name><affiliation wicri:level="1"><nlm:affiliation>Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada M3J 1P3.</nlm:affiliation><country>Canada</country><wicri:regionArea>Agent-Based Modelling Laboratory, York University, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author></analytic><series><title level="j">Scientific reports</title><idno type="eISSN">2045-2322</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Canada</term><term>Child</term><term>Child, Preschool</term><term>Disease Outbreaks (prevention & control)</term><term>Female</term><term>Humans</term><term>Infant</term><term>Infant, Newborn</term><term>Influenza A virus (immunology)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Male</term><term>Middle Aged</term><term>Pandemics (prevention & control)</term><term>Vaccination (methods)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Canada</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Flambées de maladies ()</term><term>Grippe humaine ()</term><term>Grippe humaine (immunologie)</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Nourrisson</term><term>Nouveau-né</term><term>Pandémies ()</term><term>Vaccination ()</term><term>Vaccins antigrippaux (immunologie)</term><term>Virus de la grippe A (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Grippe humaine</term><term>Vaccins antigrippaux</term><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A virus</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza, Human</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Canada</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Humans</term><term>Infant</term><term>Infant, Newborn</term><term>Male</term><term>Middle Aged</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Canada</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Flambées de maladies</term><term>Grippe humaine</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Nourrisson</term><term>Nouveau-né</term><term>Pandémies</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Ongoing research and technology developments hold the promise of rapid production and large-scale deployment of strain-specific or cross-protective vaccines for novel influenza viruses. We sought to investigate the impact of early vaccination on age-specific attack rates and evaluate the outcomes of different vaccination strategies that are influenced by the level of single or two-dose vaccine-induced protections. We developed and parameterized an agent-based model for two population demographics of urban and remote areas in Canada. Our results demonstrate that there is a time period before and after the onset of epidemic, during which the outcomes of vaccination strategies may differ significantly and are highly influenced by demographic characteristics. For the urban population, attack rates were lowest for children younger than 5 years of age in all vaccination strategies. However, for the remote population, the lowest attack rates were obtained for adults older than 50 years of age in most strategies. We found that the reduction of attack rates following the start of vaccination campaigns during the epidemic depends critically on the disease transmissibility, suggesting that for a sufficiently high transmissibility, vaccine delivery after the onset of epidemic has little or no effect, regardless of the population demographics. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26658016</PMID><DateCompleted><Year>2016</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><PubDate><Year>2015</Year><Month>Dec</Month><Day>14</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Strategies for Early Vaccination During Novel Influenza Outbreaks.</ArticleTitle><Pagination><MedlinePgn>18062</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/srep18062</ELocationID><Abstract><AbstractText>Ongoing research and technology developments hold the promise of rapid production and large-scale deployment of strain-specific or cross-protective vaccines for novel influenza viruses. We sought to investigate the impact of early vaccination on age-specific attack rates and evaluate the outcomes of different vaccination strategies that are influenced by the level of single or two-dose vaccine-induced protections. We developed and parameterized an agent-based model for two population demographics of urban and remote areas in Canada. Our results demonstrate that there is a time period before and after the onset of epidemic, during which the outcomes of vaccination strategies may differ significantly and are highly influenced by demographic characteristics. For the urban population, attack rates were lowest for children younger than 5 years of age in all vaccination strategies. However, for the remote population, the lowest attack rates were obtained for adults older than 50 years of age in most strategies. We found that the reduction of attack rates following the start of vaccination campaigns during the epidemic depends critically on the disease transmissibility, suggesting that for a sufficiently high transmissibility, vaccine delivery after the onset of epidemic has little or no effect, regardless of the population demographics. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laskowski</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada M3J 1P3.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Mathematical Sciences, University of Cincinnati, Cincinnati OH, 45221 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charland</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Medicago Inc., 1020 Route de l'Église, Bureau 600, Quebec, Quebec, Canada GIV 3V9.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moghadas</LastName><ForeName>S M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada M3J 1P3.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>06</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26658016</ArticleId><ArticleId IdType="pii">srep18062</ArticleId><ArticleId IdType="doi">10.1038/srep18062</ArticleId><ArticleId IdType="pmc">PMC4677284</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>PLoS One. 2014;9(3):e92153</Citation><ArticleIdList><ArticleId IdType="pubmed">24667168</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Place. 2014 Mar;26:53-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24370747</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiol Infect. 2015 Mar;143(4):757-65</Citation><ArticleIdList><ArticleId IdType="pubmed">25703398</ArticleId></ArticleIdList></Reference><Reference><Citation>Plant Biotechnol J. 2010 Jun;8(5):607-19</Citation><ArticleIdList><ArticleId IdType="pubmed">20199612</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Public Health. 2007;7:208</Citation><ArticleIdList><ArticleId IdType="pubmed">17697389</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2010 Sep;4(5):249-58</Citation><ArticleIdList><ArticleId IdType="pubmed">20716156</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2007 Oct 4;357(14):1373-81</Citation><ArticleIdList><ArticleId IdType="pubmed">17914038</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2007 Jan 15;165(2):212-21</Citation><ArticleIdList><ArticleId IdType="pubmed">17088311</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Open. 2012 Sep 01;2(5):null</Citation><ArticleIdList><ArticleId IdType="pubmed">22942233</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med. 2009;7:73</Citation><ArticleIdList><ArticleId IdType="pubmed">19954514</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2006 Jan 28;367(9507):303-13</Citation><ArticleIdList><ArticleId IdType="pubmed">16443037</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 2010 Feb 9;182(2):131-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19959592</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2005 Oct 1;366(9492):1165-74</Citation><ArticleIdList><ArticleId IdType="pubmed">16198765</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Dec 26;369(26):2564-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24224560</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Jul 1;29 Suppl 1:A1</Citation><ArticleIdList><ArticleId IdType="pubmed">21684419</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2000 Oct 4;284(13):1677-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11015798</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 1995 Jun;1(6):583-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7585127</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2006 Sep 16;368(9540):991-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16980114</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2004 Aug;4(8):499-509</Citation><ArticleIdList><ArticleId IdType="pubmed">15288823</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2005 Sep 8;437(7056):209-14</Citation><ArticleIdList><ArticleId IdType="pubmed">16079797</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014;9(2):e89651</Citation><ArticleIdList><ArticleId IdType="pubmed">24586937</ArticleId></ArticleIdList></Reference><Reference><Citation>Anim Health Res Rev. 2012 Dec;13(2):181-95</Citation><ArticleIdList><ArticleId IdType="pubmed">23253165</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20365-70</Citation><ArticleIdList><ArticleId IdType="pubmed">19918065</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Res Notes. 2011 Dec 13;4:537</Citation><ArticleIdList><ArticleId IdType="pubmed">22166307</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2011 Aug 15;204(4):574-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21791660</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Rev. 2013 Jul;26(3):476-92</Citation><ArticleIdList><ArticleId IdType="pubmed">23824369</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Oct 13;29(44):7733-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21835220</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Immunol. 2014 Oct;154(2):164-77</Citation><ArticleIdList><ArticleId IdType="pubmed">25128897</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2005 Feb 26-Mar 4;365(9461):773-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15733718</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2003 Jun 15;36(12):1552-61</Citation><ArticleIdList><ArticleId IdType="pubmed">12802755</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2009 May;9(5):291-300</Citation><ArticleIdList><ArticleId IdType="pubmed">19393959</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Chemother. 2006 Aug;12(4):167-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16944252</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2003 May 1;21(16):1769-75</Citation><ArticleIdList><ArticleId IdType="pubmed">12686092</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2002 Mar 15;20(13-14):1831-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11906772</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2004 Apr 1;159(7):623-33</Citation><ArticleIdList><ArticleId IdType="pubmed">15033640</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li><li>États-Unis</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Laskowski, M" sort="Laskowski, M" uniqKey="Laskowski M" first="M" last="Laskowski">M. Laskowski</name></noRegion><name sortKey="Charland, N" sort="Charland, N" uniqKey="Charland N" first="N" last="Charland">N. Charland</name><name sortKey="Moghadas, S M" sort="Moghadas, S M" uniqKey="Moghadas S" first="S M" last="Moghadas">S M Moghadas</name></country><country name="États-Unis"><noRegion><name sortKey="Xiao, Y" sort="Xiao, Y" uniqKey="Xiao Y" first="Y" last="Xiao">Y. Xiao</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000181 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000181 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeCanadaV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26658016
|texte= Strategies for Early Vaccination During Novel Influenza Outbreaks.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26658016" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV3
| This area was generated with Dilib version V0.6.35. |  |